Surprised shareholders target Allergan over generics pricing probe

Fierce Pharma ------- Allergan no longer owns Actavis, having unloaded the generics unit to Teva. That hasn't kept the drugmaker from facing potential fallout from shareholders who say Allergan’s share price has been stung by questionable pricing practices when it did. Former employee Andrew Ormond launched a class action suit against the drugmaker, arguing its shares were “artificially inflated” between Feb. 25, 2014, and Nov. 2, 2016. Several Allergan press releases and filings from the company praised its own performance during that time, but the lawsuit claims that behind the scenes, things weren’t all that genial. To learn more click on the picture below to read the article.